• Explore /
  • Poster
  • / Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Abstract Poster

Authors

null

Sylvia Adams

NYU Langone Medical Center, New York, NY

Sylvia Adams , Sherene Loi , Deborah Toppmeyer , David W. Cescon , Michele De Laurentiis , Rita Nanda , Eric P. Winer , Hirofumi Mukai , Kenji Tamura , Anne Armstrong , Minetta C. Liu , Hiroji Iwata , Larisa Ryvo , Pauline Wimberger , Deborah Card , Yu Ding , Vassiliki Karantza , Peter Schmid

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02447003

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1088)

DOI

10.1200/JCO.2017.35.15_suppl.1088

Abstract #

1088

Poster Bd #

80

Abstract Disclosures

Similar Posters

First Author: Maria Cortes

First Author: Shipra Gandhi

First Author: Ryan Huu-Tuan Nguyen

First Author: Shao Zhimin